cagrilintide novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major ECO 2026 - Assessing Cardiovascular
Description
The data we have comes largely from comparing separate trial populations, which introduces variables like differences in baseline BMI, diet and exercise protocols, and participant demographics
Under refrigerated storage at 28C and protected from light and freeze-thaw cycles, reconstituted solution is generally used within four weeks
Use within 28 days, then reconstitute next vial
Whats Inside the Wolverine Stack
:max_bytes(150000):strip_icc()/GettyImages-2197227432-6dabff12e088403c8032fbae8a53811d.jpg)
